MDT

87.95

+0.96%↑

117.5

+2.09%↑

VEEV

158.5

+4.65%↑

HQY

79.86

+2.23%↑

TLRY

6.73

+2.28%↑

MDT

87.95

+0.96%↑

117.5

+2.09%↑

VEEV

158.5

+4.65%↑

HQY

79.86

+2.23%↑

TLRY

6.73

+2.28%↑

MDT

87.95

+0.96%↑

117.5

+2.09%↑

VEEV

158.5

+4.65%↑

HQY

79.86

+2.23%↑

TLRY

6.73

+2.28%↑

MDT

87.95

+0.96%↑

117.5

+2.09%↑

VEEV

158.5

+4.65%↑

HQY

79.86

+2.23%↑

TLRY

6.73

+2.28%↑

MDT

87.95

+0.96%↑

117.5

+2.09%↑

VEEV

158.5

+4.65%↑

HQY

79.86

+2.23%↑

TLRY

6.73

+2.28%↑

Kodu・Aktsiate loetelu・Mirati Therapeutics Inc

Mirati Therapeutics Inc

Suletud

SektorTervishoid

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

Max

Soovitused
By TipRanks
Soovitused	Neutraalne
12 kuu keskmine prognoos	-0.05% downside

Uudiste sentiment

By Acuity

50%

154 / 348 Pingereas Healthcare

Mirati Therapeutics Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

13. apr 2026, 23:25 UTC

Uudisväärsed sündmused

Westpac Expects Higher Loan Losses as Iran Conflict Slows Australian Economy -- Update

13. apr 2026, 22:45 UTC

Uudisväärsed sündmused

Westpac Expects Higher Loan Losses as Iran Conflict Slows Australian Economy

13. apr 2026, 18:03 UTC

Tulu

Louis Vuitton Owner Logs Weak Sales as Middle East War Takes Toll -- 2nd Update

13. apr 2026, 23:58 UTC

Tulu

Review & Preview: Earnings Time -- Barrons.com

13. apr 2026, 23:49 UTC

Market Talk

Nikkei May Rise After Overnight Gains on Wall Street -- Market Talk

13. apr 2026, 23:33 UTC

Market Talk

Uudisväärsed sündmused

Gold Edges Higher Amid Dollar Weakness -- Market Talk

13. apr 2026, 23:20 UTC

Market Talk

Uranium Stocks Seen Benefiting From Energy Security Concerns -- Market Talk

13. apr 2026, 23:01 UTC

Tulu

Aura: Capex Guidance Revised From $111M and $130M to New Range of $262M and $314M >AURA33.SA.BR

13. apr 2026, 23:01 UTC

Tulu

Aura Minerals: Announces Update to Capex Guidance Including Construction of the Era Dorada Project

13. apr 2026, 23:01 UTC

Tulu

Aura: Will Update Cap Expenditure Guidance to Include the Project's Construction Phase >AURA33.SA.BR

13. apr 2026, 22:21 UTC

Omandamised, ülevõtmised, äriostud

Chevron Swaps Offshore Gas Stakes to Boost Venezuelan Heavy-Oil Footprint -- Update

13. apr 2026, 21:53 UTC

Tulu

MarketWise, Inc.: Affirms FY 2026 Guidance, Including Div Target to Class A Hldrs of $1.80 per Shr

13. apr 2026, 21:53 UTC

Tulu

MarketWise, Inc.: Paid Subscribers Were 381,000 at March 31 Compared to 374,000 at Dec 31, 2025, Active Free Subscribers Were 2.0M at March 31 >MKTW

13. apr 2026, 21:53 UTC

Tulu

MarketWise, Inc.: 1Q Billings Increased Approximately 15% Yr-over-Yr to Approximately $81M

13. apr 2026, 21:53 UTC

Tulu

MarketWise, Inc.: Preliminary Selected Unaudited 1Q Paid Subscribers Returning to Growth

13. apr 2026, 21:26 UTC

Uudisväärsed sündmused

U.S. Oil Blockade Is Set to Boost American Exports -- and Prices at the Pump -- WSJ

13. apr 2026, 21:23 UTC

Tulu

Johnson & Johnson Earnings: Oncology Powers Growth, but Talc Lawsuits Persist -- Barrons.com

13. apr 2026, 21:16 UTC

Tulu

Goldman Sachs Reports Record Quarter in Banking and Trading -- 4th Update

13. apr 2026, 20:50 UTC

Market Talk

Uudisväärsed sündmused

Basic Materials Roundup: Market Talk

13. apr 2026, 20:50 UTC

Market Talk

Auto & Transport Roundup: Market Talk

13. apr 2026, 20:34 UTC

Tulu

Victory Capital: 1Q Long-Term AUM Net Flows of -$457M >VCTR

13. apr 2026, 20:34 UTC

Tulu

Victory Capital: March Avg Total AUM Was $315.3B, Avg Other Assets $3.2B, Avg Total Client Assets $318.5B >VCTR

13. apr 2026, 20:34 UTC

Tulu

Victory Capital Holdings, Inc.: Total Assets Under Management of $309.8B, Other Assets $3.3B, Total Client Assets of $313.1B as of March 31 >VCTR

13. apr 2026, 19:59 UTC

Market Talk

Canada Consumers Sour Prior to Big Energy-Price Jump -- Market Talk

13. apr 2026, 19:50 UTC

Market Talk

Uudisväärsed sündmused

Oil Futures Pull Back From Highs on Hopes for Talks -- Market Talk

13. apr 2026, 19:27 UTC

Market Talk

Uudisväärsed sündmused

Correction to Precious Metals Market Talk on April 9

13. apr 2026, 19:14 UTC

Market Talk

U.S. Natural Gas Futures Settle Lower on Mild Weather -- Market Talk

13. apr 2026, 18:59 UTC

Market Talk

Uudisväärsed sündmused

Fed's Goolsbee: Don't Be Surprised If Consumer Confidence Sours -- Market Talk

13. apr 2026, 18:59 UTC

Market Talk

Uudisväärsed sündmused

Fed's Goolsbee: Oil Shows People Expect Short Term Conflict in Iran -- Market Talk

13. apr 2026, 18:43 UTC

Market Talk

Precious Metals Lose Ground as U.S. Blockade in Hormuz Gets Underway -- Market Talk

Võrdlus sarnastega

Hinnamuutus

Mirati Therapeutics Inc Prognoos

Hinnasiht

By TipRanks

-0.05% langus

12 kuu keskmine prognoos

Keskmine 58.67 USD -0.05%

Kõrge 59 USD

Madal 58 USD

Põhineb 5 Wall Streeti analüütiku instrumendi Mirati Therapeutics Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Neutraalne

5 ratings

Osta

Hoia

Müü

Põhineb 5 analüütiku instrumendi Mirati Therapeutics Inc aktsia reitingul - viimase 3 kuu andmed.

Sentiment

By Acuity

154 / 348 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

EBITDA

Ärikasum

Ettevõttest Mirati Therapeutics Inc

Mirati Therapeutics, Inc. is a clinical-stage oncology company. It is focused on developing therapeutics to address the genetic and immunological promoters of cancer. Its clinical programs consist of product candidates, including Adagrasib (MRTX849), MRTX1133, and Sitravatinib. MRTX849 is an oral small-molecule therapy designed to shrink difficult-to-treat cancers harboring the KRAS G12C mutation. MRTX1133 is a small molecule-inhibitor of the KRASG12D mutation, designed to treat patients with unmet need. Sitravatinib is a spectrum-selective receptor tyrosine kinase (RTK) inhibitor that can stimulate the body’s immune response to fight cancer. MRTX849 is in Phase III and Phase I/II clinical trials and MRTX1133 is in preclinical development. Sitravatinib is in a Phase III clinical trial, and Phase I/II clinical trials. It also has additional preclinical discovery programs, which includes first-in-class and best-in-class product candidates designed to address mutations and tumors.